Pfizer Inc. has the cash to spend on business development, and CEO Albert Bourla told investors the company is aiming to sign deals that will add $25bn of risk-adjusted revenue to the top line by 2030. During the firm’s fourth quarter sales and earnings call on 8 February, Pfizer's management outlined the current thinking on allocating the windfall of cash it has stockpiled.
The success of Pfizer's COVID-19 vaccine Comirnaty and oral antiviral Paxlovid (nirmatrelvir/ritonavir) have strengthened the company's financial flexibility to do...








